Drug intelligence / Profile preview

B-3E10

Development stage: Preclinical
Lead developer: Yifan Pharmaceutical
Administration: Intravenous, Intrathecal, Intracerebroventricular, Parenteral, Injection, Infusion

Overview

B-3E10 is a biologic drug candidate currently in the preclinical stage of development by Yifan Pharmaceutical. It is being investigated for the treatment of diabetes. As part of Yifan's metabolic disease pipeline, B-3E10 is one of several biologic assets targeting glycemic control. While the company has not publicly disclosed the specific molecular target or mechanism of action for this candidate, it is categorized within their innovative biologics portfolio alongside other metabolic treatments such as GLP-1/GIP agonists and insulin-related products.

Targets

RAD51 (RAD51 Recombinase)DNA

Beyond the preview

Go deeper on B-3E10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-3E10.

Explore the full profile